Galectin Therapeutics (NYSE:GALT) stock price target reduced to $0.75, issued a report today by Roth Capital
- Updated: September 28, 2016
Yesterday Galectin Therapeutics (NYSE:GALT) traded -38.06% lower at $1.48. The company’s 50-day moving average is $1.92 and its two hundred day average is $1.61. With the last stock price close down -4.88% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was up over the average, with 4,043,076 shares of GALT changing hands over the typical 417,641
In a report released on 09/28/2016 Roth Capital reduced the stock price target of Galectin Therapeutics (NYSE:GALT) from $3.00 to $0.75 indicating a possible downside of -0.49%.
Previously on Monday March 28, 2016, H.C. Wainwright reported on Galectin Therapeutics (NYSE:GALT) increased the target price from $0.00 to $8.00. At the time, this indicated a possible upside of 4.76%.
With a total market value of $0, Galectin Therapeutics has with a one year low of $1.08 and a one year high of $3.25 .
A total of 3 equity analysts have released a ratings update on GALT. One equity analyst rating the company a strong buy, two equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $8.33.
Brief Synopsis About Galectin Therapeutics (NYSE:GALT)
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.